Taisho still looking to increase stake in DHG

October 01, 2018 | 15:24

(0) user say

Taisho Group, one of the largest five pharmaceutical firms in Japan, expressed interest in buying an additional 2.3 per cent (3 million shares) in Hau Giang Pharmaceutical JSC (DHG).

taisho still looking to increase stake in dhg

Taisho will buy three million more DHG shares in October

While a relatively small share volume, it brings Taisho Group closer to its target of enhancing its pharmaceutical business in Asia, including Vietnam.

The transaction is expected to occur between October 2 and 31. Once successful, Taisho will increase its holding in DHG from 41.83 million shares (32 per cent), to 44.83 million shares or 34.3 per cent.

While Taisho Group is buying additional shares in DHG, Templeton Frontier Markets Fund divested 3 million shares on August 21, decreased its holding in DHG to 4.1 per cent from 6.4 per cent.

After the sale, Templeton Frontier Markets Fund lost its large shareholder position in DHG, and Taisho remained the second largest shareholder, following State Capital Investment Corporation (SCIC) with 43.31 per cent.

Taisho Group, headquartered in Tokyo, is a leading Japanese pharmaceutical company specialising in the manufacturing of pharmaceutical products and non-prescription dietary supplements from well-known brands.

In Southeast Asia, Lipovitan D (a vitamin-rich energy drink) is the company’s most famous brand. In 2015, the parent company recorded a revenue of $2.7 billion and after-tax profit of $210 million. In the local market Taisho founded an $11.8-million investment company that manufactures and distributes Lipovitan drinks.

By Kim Oanh

What the stars mean:

★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional